India's bioeconomy to reach US $300 billion by 2030: Dr. Jitendra Singh
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
ZenBio is a highly regarded science-focused company specializing in biospecimens and related services with scientific expertise
MoCRA mandates that all facilities involved in the manufacturing and processing of cosmetic products for sale in the United States
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
He advocated for a "PPP + PPP" collaboration, urging the public and private sectors within India to partner with their counterparts in other countries
Subscribe To Our Newsletter & Stay Updated